5-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-{1-[4-(morpholin-4-ylcarbonyl)phenyl]-1H-1,2,3-triazol-4-yl}-1H-indazole → 5-(1-methylpiperidin-4-yl)-3-{1-[4-(morpholin-4-ylcarbonyl)phenyl]-1H-1,2,3-triazol-4-yl}-1H-indazole

HRID 1520073Notes

Reaction equation

HRID 1520073 reaction equation
[CH3:1][N:2]1[CH2:7][CH:6]=[C:5]([C:8]2[CH:9]=[C:10]3[C:14](=[CH:15][CH:16]=2)[NH:13][N:12]=[C:11]3[C:17]2[N:18]=[N:19][N:20]([C:22]3[CH:27]=[CH:26][C:25]([C:28]([N:30]4[CH2:35][CH2:34][O:33][CH2:32][CH2:31]4)=[O:29])=[CH:24][CH:23]=3)[CH:21]=2)[CH2:4][CH2:3]1>CO.[Pd]>[CH3:1][N:2]1[CH2:7][CH2:6][CH:5]([C:8]2[CH:9]=[C:10]3[C:14](=[CH:15][CH:16]=2)[NH:13][N:12]=[C:11]3[C:17]2[N:18]=[N:19][N:20]([C:22]3[CH:23]=[CH:24][C:25]([C:28]([N:30]4[CH2:35][CH2:34][O:33][CH2:32][CH2:31]4)=[O:29])=[CH:26][CH:27]=3)[CH:21]=2)[CH2:4][CH2:3]1

Participants

4

Procedure

5-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-{1-[4-(morpholin-4-ylcarbonyl)phenyl]-1H-1,2,3-triazol-4-yl}-1H-indazole (20 mg; 0.04 mmol; 1.0 eq.) was dissolved in MeOH (3 mL) and Pd/C (moistened, 50% water; 100 mg) was added. The reaction mixture was hydrogenenated at RT for two days in a Parr instrument (35 bars). Reaction mixture was filtered through a celite pad and dried under vacuum to give the title compound as a beige solid (14 mg, 70%). 1H NMR (300 MHz, DMSO-d6) δ 9.37 (s, 1H), 8.25-8.09 (m, 3H), 7.73-7.62 (m, 2H), 7.64-7.49 (m, 1H), 7.40-7.29 (m, 1H), 3.81-3.39 (m, 8H), 2.98-2.56 (m, 4H), 2.22 (s, 3H), 2.06-1.66 (m, 5H). HPLC (Condition A): Rt 3.86 min (purity 87.8%). MS (ESI+): 472.3, MS (ESI−): 470.2.

Workup

  1. customReaction mixture
  2. filtrationwas filtered through a celite pad
  3. customdried under vacuum

Sources & evidence

ORD record
ord-c2c0991744d14f368f1059433e67d400
Source dataset
uspto-grants-2015_07
Patent number
US09073892B2

Reaction notes

Loading…